Panna Sharma - Sep 19, 2025 Form 4 Insider Report for Lantern Pharma Inc. (LTRN)

Role: President & CEO, Director
Signature: /s/ Panna Sharma
Stock symbol: LTRN
Transactions as of: Sep 19, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/23/2025, 04:05 PM
Previous filing: Jul 17, 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SHARMA PANNA	President & CEO, Director	1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS	/s/ Panna Sharma	2025-09-22	0001157989

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LTRN	Stock Option (Right to Buy)	Disposed to Issuer	$0	-76.6K	-100%	$0.00	0	Jun 15, 2020	Common Stock	76.6K	$15.00	Direct	F1
transaction	LTRN	Stock Option (Right to Buy)	Award	$0	+76.6K		$0.00	76.6K	Jun 15, 2020	Common Stock	76.6K	$5.04	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date).

Content

The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and one-third of the option vested 180 days from the grant date with the remaining two-thirds of the option vesting in equal monthly increments over the period commencing the 181st day after the grant date and ending 30 months thereafter (or 36 months after the grant date).